Compare CERS & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERS | RZLT |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 326.4M |
| IPO Year | 1997 | N/A |
| Metric | CERS | RZLT |
|---|---|---|
| Price | $2.23 | $3.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $4.00 | ★ $9.14 |
| AVG Volume (30 Days) | 1.1M | ★ 3.2M |
| Earning Date | 02-27-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $199,191,000.00 | N/A |
| Revenue This Year | $25.31 | N/A |
| Revenue Next Year | $9.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.03 | N/A |
| 52 Week Low | $1.12 | $1.07 |
| 52 Week High | $2.96 | $11.46 |
| Indicator | CERS | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 59.72 |
| Support Level | $2.05 | $2.95 |
| Resistance Level | $2.26 | $3.24 |
| Average True Range (ATR) | 0.14 | 0.30 |
| MACD | -0.03 | 0.13 |
| Stochastic Oscillator | 39.39 | 80.62 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.